FBLG FibroBiologics, Inc.: institutional ownership and insider trading
16 funds reported holding $305K of FibroBiologics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $60.9K, with 3 new positions and 4 funds selling out; over the last 12 months insiders bought $120K and sold $0 on the open market.
FBLG revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.12M, EPS -0.66
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.00M, EPS -1.33
- Quarter ended Dec 31, 2025: revenue n/a, net income −$3.24M, EPS 4.83
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.78M, EPS -0.13
Largest institutional holders of FBLG
- Cascade Financial Partners, LLC — $103K
- Fund Evaluation Group, LLC — $49.1K
- IFP Advisors, Inc — $35.1K
- GEODE CAPITAL MANAGEMENT, LLC — $28.7K
- VANGUARD CAPITAL MANAGEMENT LLC — $26.3K
- Qube Research & Technologies Ltd — $23.0K
- BlackRock, Inc. (BLK) — $17.3K
- BARCLAYS PLC (BCS, BCLYF) — $6.86K
- VANGUARD FIDUCIARY TRUST CO — $6.05K
- Tower Research Capital LLC (TRC) — $4.48K
Recent FBLG insider trades
- Mar 4, 2026: Khoja Hamid bought 30,000 shares ($11.4K)
- Mar 4, 2026: O'heeron Pete bought 51,500 shares ($19.6K)
- Mar 2, 2026: Davis Jason bought 70,000 shares ($28.7K)
- Feb 27, 2026: Garcia Ruben A bought 40,000 shares ($13.2K)
5%+ owners
- Armistice Capital, LLC: 10.0% (Schedule 13G, filed Aug 14, 2026)
- Hamid Khoja: 7.5% (Schedule 13D, filed Sep 17, 2026)